Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. It had an exceptional launch and generated £1.2 billion in sales in 2023. In the first six months of 2024 ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Arexvy was the first vaccine approved to prevent respiratory syncytial virus (RSV). RSV is a common virus that usually causes mild cold-like symptoms. These symptoms can be more severe in babies ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients.

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

The Canada Pharmaceutical Market, valued at USD 51.56 billion in 2024, is projected to reach USD 76.9 billion by 2030, ...

Well in advance of the fall and winter RSV season, GSK's vaccine Arexvy is now available in major U.S. retail pharmacies, the company said.

Like many adults over 60, Tom, a patient advocate for GSK, was unfamiliar with respiratory syncytial virus (RSV) when he tested positive for the common, contagious respiratory virus in the fall of ...

Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. Arexvy had an exceptional launch and generated £1.2 billion in sales in 2023.